InterCure (IL:INCR)
TASE:INCR
Top Page
Intercure
(TASE:INCR)
Select Model
Select Model
Rating:44Neutral
Price Target:
305.00
▼(-40.68% Downside)
Action:ReiteratedDate:01/08/26
The score is held down primarily by weak financial performance (declining revenue, negative profitability, and negative operating/free cash flow) and a strongly bearish technical setup (below all key moving averages with negative MACD). Valuation provides limited signal because P/E and dividend yield data are unavailable.
Positive Factors
Vertical integration
Owning cultivation, production and distribution creates durable control over product quality, supply consistency and pricing. This vertical model can sustain gross margins, lower unit costs over time, and protect against third-party supply disruptions as the company scales domestically and abroad.
Negative Factors
Declining revenue and negative margins
Sustained declines in revenue and compressing gross and operating margins indicate structural demand or cost issues. Persistent unprofitability erodes retained earnings, limits reinvestment capacity, and weakens competitive positioning versus better-funded peers over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration
Owning cultivation, production and distribution creates durable control over product quality, supply consistency and pricing. This vertical model can sustain gross margins, lower unit costs over time, and protect against third-party supply disruptions as the company scales domestically and abroad.
Read all positive factors
Intercure (INCR) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪129.49M
Dividend YieldN/A
Average Volume (3M)91.19K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue GrowthN/A
EPS GrowthN/A
CountryIL
Employees320
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,681,335
10 Day Avg. Volume173,192
30 Day Avg. Volume91,185
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.65
Price to Sales (P/S)1.09
P/FCF Ratio-3.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Intercure Business Overview & Revenue Model
Company Description
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract ...
How the Company Makes Money
Intercure generates revenue through multiple key streams, primarily by selling its medical cannabis products to patients and pharmacies. The company benefits from its vertically integrated business model, which includes cultivation, production, an...
Intercure Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 243.12M | 238.84M | 355.55M | 388.68M | 219.68M | 65.03M |
| Gross Profit | 40.61M | 30.23M | 105.09M | 155.08M | 91.13M | 31.98M |
| EBITDA | -79.49M | -51.31M | -23.90M | 70.23M | 31.17M | -34.53M |
| Net Income | -70.93M | -67.80M | -61.96M | 44.82M | 4.69M | -37.23M |
Balance Sheet | ||||||
| Total Assets | 751.76M | 762.57M | 786.61M | 958.01M | 686.32M | 326.27M |
| Cash, Cash Equivalents and Short-Term Investments | 51.58M | 78.65M | 101.33M | 232.79M | 196.55M | 38.26M |
| Total Debt | 179.34M | 211.40M | 195.68M | 255.16M | 108.91M | 6.68M |
| Total Liabilities | 319.52M | 364.90M | 329.55M | 436.53M | 227.13M | 34.16M |
| Stockholders Equity | 431.15M | 396.97M | 455.11M | 501.31M | 448.03M | 274.51M |
Cash Flow | ||||||
| Free Cash Flow | 8.95M | -71.30M | -56.25M | 31.52M | 10.99M | -13.04M |
| Operating Cash Flow | 12.20M | -66.93M | -53.63M | 51.27M | 25.02M | 7.80M |
| Investing Cash Flow | -4.33M | 17.69M | 4.77M | -142.50M | -65.21M | -22.76M |
| Financing Cash Flow | -34.85M | 26.45M | -82.89M | 120.45M | 197.94M | 25.29M |
Intercure Technical Analysis
Negative
514.20
Price Trends
266.56
Negative
327.43
Negative
423.56
Negative
Market Momentum
-9.43
Negative
33.27
Neutral
40.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Negative. The current price of 514.2 is above the 20-day moving average (MA) of 245.07, above the 50-day MA of 266.56, and above the 200-day MA of 423.56, indicating a bearish trend. The MACD of -9.43 indicates Negative momentum. The RSI at 33.27 is Neutral, neither overbought nor oversold. The STOCH value of 40.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:INCR.
Intercure Peers Comparison
UnderperformOutperform
Sector (51)
IL:INCR
Intercure
236.60
-238.00
-50.15%
IL:TGTR
Together
269.30
-135.90
-33.54%
IL:TKUN
Tikun Olam Canb
2,167.00
2,130.00
5756.76%
IL:CNZN.M
Canzon-M
170.00
56.10
49.25%
IL:NXTG.M
Nextage-M
55.00
-56.70
-50.76%
IL:SEMG
Seach Medical
251.60
0.11
0.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.